Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117090

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

A Kubota, Y Yamada, S Kagimoto, A Shimatsu, M Imamura, K Tsuda, H Imura, S Seino, and Y Seino

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Kubota, A. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Yamada, Y. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Kagimoto, S. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Shimatsu, A. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Imamura, M. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Tsuda, K. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Imura, H. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Seino, S. in: JCI | PubMed | Google Scholar

Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine, Japan.

Find articles by Seino, Y. in: JCI | PubMed | Google Scholar

Published March 1, 1994 - More info

Published in Volume 93, Issue 3 on March 1, 1994
J Clin Invest. 1994;93(3):1321–1325. https://doi.org/10.1172/JCI117090.
© 1994 The American Society for Clinical Investigation
Published March 1, 1994 - Version history
View PDF
Abstract

The presence of somatostatin receptors has been demonstrated in various endocrine tumors as well as in normal tissues. We recently have cloned five human somatostatin receptor subtypes (SSTR1-SSTR5). These mRNAs are expressed in a tissue-specific manner. In this study, we have determined the somatostatin receptor subtypes expressed in various endocrine tumors using a reverse transcriptase polymerase chain reaction method. In two cases of glucagonoma and its metastatic lymph nodes in one case, all the SSTR subtype mRNAs except SSTR5 mRNA were expressed. In four cases of insulinoma, SSTR1 and SSTR4 mRNAs were detected, but SSTR2 mRNA was not detected in one case and SSTR3 mRNA was not detected in two cases, indicating a heterogeneous expression of SSTR subtypes in insulinomas. Interestingly, SSTR3 mRNA, which is highly expressed in rat pancreatic islets, is not expressed in normal human pancreatic islets, while SSTR1, SSTR2, and SSTR4 mRNAs are expressed. In three cases of pheochromocytoma, SSTR1 and SSTR2 mRNAs were detected, showing an expression pattern identical to that of normal adrenal gland. In a carcinoid, SSTR1 and SSTR4 mRNAs were detected. We have also found that human SSTR2 shows a high affinity for SMS 201-995, which has been used clinically for the treatment of endocrine tumors. Since SMS 201-995 was effective in the treatment of a patient with glucagonoma in which SSTR2 mRNA was present, but had no effect in a patient with carcinoid in which SSTR2 mRNA was not detected, this study suggests that the efficacy of SMS 201-995 may depend, at least in part, on the expression of SSTR2 in tumors.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1321
page 1321
icon of scanned page 1322
page 1322
icon of scanned page 1323
page 1323
icon of scanned page 1324
page 1324
icon of scanned page 1325
page 1325
Version history
  • Version 1 (March 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts